Research programme: autoimmune disorder therapeutics - Kineta RLB

Drug Profile

Research programme: autoimmune disorder therapeutics - Kineta RLB

Latest Information Update: 25 Apr 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kineta RLB
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders

Most Recent Events

  • 15 Apr 2014 Early research in Autoimmune disorders in USA (unspecified route)
  • 15 Apr 2014 Kineta and RLB Holdings form Kineta RLB for the development of therapeutics for the treatment of Autoimmune diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top